This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Prognosis

Authoring team

The prognosis in myasthenia gravis is very variable. The use of immunosuppressive drugs has steadily improved outcome in recent years.

Remission or substantial improvement can be expected in 80% of patients. For those with associated thymoma, the 5 year survival is approximately 30 %.

Patients with older age of onset and comorbidities, including other associated autoimmune diseases, typically have a poorer prognosis.

Reference

  1. Hansen JS, Danielsen DH, Somnier FE, et al. Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve. 2016 Jan;53(1):73-7.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.